Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D. Solomon, Anna Maria Langkilde|New England Journal of Medicine|2022Cited by 2.6k
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialOfri Mosenzon, Itamar Raz, Stephen D. Wiviott et al.|The Lancet Diabetes & Endocrinology|2019Cited by 673
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trialHiddo J.L. Heerspink, Rey Isidto, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2019Cited by 216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C. Wheeler, Hiddo J.L. Heerspink, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2020Cited by 189
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W. Ostrominski, Muthiah Vaduganathan, Jorge Thierer et al.|JACC Heart Failure|2023Cited by 39